Intervention

HLX10

ClinicalTrials.gov intervention label

Clinical trials6

Recruiting0

Common conditions6

Lead sponsors shown2

Clinical trials

6 shown

A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung CancerNCT05354700 · 2023-03-29

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC PatientsNCT05443646 · 2022-09-23

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung CancerNCT05353257 · 2022-05-17

ACTIVE_NOT_RECRUITING

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)NCT04301739 · 2020-04-17

NOT_YET_RECRUITING

A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLCNCT04063163 · 2019-09-12

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLCNCT04033354 · 2019-08-14

Common conditions

Extensive Stage Small Cell Lung Cancer1 Limited Stage Small Cell Lung Cancer1 Limited-Stage Small Cell Lung Cancer1 Small-cell Lung Cancer1 Squamous Non Small Cell Lung Cancer1 Triple Negative Breast Cancer1

Leading sponsors

Shanghai Henlius Biotech5 Cancer Institute and Hospital, Chinese Academy of Medical Sciences1

Trial status mix

UNKNOWN3

ACTIVE_NOT_RECRUITING1

COMPLETED1

NOT_YET_RECRUITING1

Phase mix

PHASE34

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.